Notice of Appeal

Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory myeloma [Review of TA658] [ID4067]

 NICE has received 2 appeals, that fall within one or more of the two strictly limited grounds for appeal, against the Final Draft Guidance   on the above technology from the following organisations:

• Sanofi
• Myeloma UK and UK Myeloma Society

 The appeal panel will convene on 23 September 2024 at 10:00 via Zoom to hear oral representations from the appellants.

 Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing.

 Where possible, requests to attend should be made using the registration link that will be available on our website from 17 July 2024   The registration period for this appeal will end at 4:00pm on 16 September 2024.

 Further details relating to public attendance at this appeal are available on the same webpage as above.